Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | GALR2 | O43603 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18162511 | 0.89 | LMNA (0.53) | BPTFROCK2CCNE1CDK2ROCK1 | |
| SCHEMBL18162433 | 0.86 | MEN1 (0.47) | CCNE1CDK2HTR2AHTR2CKMT2A | |
| SCHEMBL18153340 | 0.84 | ROCK2 (0.65) | BPTFROCK2CCNE1CDK2ROCK1 | |
| SCHEMBL23221453 | 0.81 | BPTF (0.54) | BPTFROCK2CCNE1CDK2HTR2A | |
| SCHEMBL3242747 | 0.81 | GALR2 (0.60) | ROCK2HTR2AROCK1HTR2CKMT2A | |
| SCHEMBL18063492 | 0.81 | BPTF (0.51) | BPTFROCK2CCNE1CDK2HTR2A | |
| SCHEMBL18162562 | 0.80 | PKM (0.58) | CCNE1CDK2KMT2AMEN1MAPT | |
| SCHEMBL20042176 | 0.80 | ROCK2 (0.67) | BPTFROCK2CCNE1CDK2ROCK1 | |
| SCHEMBL18153408 | 0.80 | BPTF (0.52) | BPTFROCK2CCNE1CDK2HTR2A | |
| SCHEMBL6784463 | 0.79 | HTR2C (0.56) | HTR2AHTR2CKMT2AMEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | BPTF 2828/4885ROCK2 2833/4885CCNE1 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.